A Randomized, Double-blind, Multicenter, Parallel Group, Balanced, Stratified Phase 3 Study to Evaluate the Efficacy and the Safety of Single IV Doses of Palonosetron 0.025 mg, 0.050 mg, and 0.075 mg versus Placebo to Prevent Postoperative Nausea and Vomiting Following Elective Gynecologic or Breast Surgery
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2011
At a glance
- Drugs Palonosetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 13 Jul 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2005-000593-41).
- 05 Nov 2010 New trial record.